Isoniazid
- Generic Name
- Isoniazid
- Brand Names
- Isonarif, Isotamine, Isotamine B, Rifamate, Rifater
- Drug Type
- Small Molecule
- Chemical Formula
- C6H7N3O
- CAS Number
- 54-85-3
- Unique Ingredient Identifier
- V83O1VOZ8L
- Background
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
- Indication
Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.
- Associated Conditions
- Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis
Tuberculosis Prevention for HIV Infected Adults
- Conditions
- HIV InfectionsTuberculosis
- Interventions
- First Posted Date
- 2003-03-28
- Last Posted Date
- 2012-10-22
- Target Recruit Count
- 1148
- Registration Number
- NCT00057122
- Locations
- 🇿🇦
Chris Hani Baragwanath Hospital, Soweto, South Africa
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- HIV Infections
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: atazanavir/ritonavir dosage #1Drug: tipranavir/ritonavirDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: darunavir/ritonavir dosage #3Drug: levoflaxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
- Conditions
- Tuberculosis
- Interventions
- Drug: RPT + INH once weekly for 3 months given by DOT
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 8053
- Registration Number
- NCT00023452
- Locations
- 🇺🇸
Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
🇺🇸Michael Debakey Veterans Affairs Medical Center, Houston, Texas, United States
🇺🇸Seattle King County Health Department, Seattle, Washington, United States
TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB
- Conditions
- HIV InfectionsTuberculosis
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-13
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 150
- Registration Number
- NCT00023348
- Locations
- 🇺🇸
Denver Department of Public Health and Hospitals, Denver, Colorado, United States
🇺🇸Hines VA Medical Center, Hines, Illinois, United States
🇨🇦University of Manitoba, Winnipeg, Manitoba, Canada
TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine
- Conditions
- Tuberculosis
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-13
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 36
- Registration Number
- NCT00023387
- Locations
- 🇺🇸
LA County/USC Medical Center, Los Angeles, California, United States
🇺🇸Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-05
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 1000
- Registration Number
- NCT00023335
- Locations
- 🇺🇸
LA County/USC Medical Center, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
- Conditions
- HIV InfectionsTuberculosis
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 525
- Registration Number
- NCT00000796
- Locations
- 🇺🇸
Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
🇺🇸Bronx Lebanon Hosp Ctr, Bronx, New York, United States
Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
- Conditions
- HIV InfectionsTuberculosis
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 2000
- Registration Number
- NCT00000636
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Philadelphia FIGHT, Philadelphia, Pennsylvania, United States
🇺🇸Boston Dept of Health and Hosps, Boston, Massachusetts, United States
Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
- Conditions
- TuberculosisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 2000
- Registration Number
- NCT00000638
- Locations
- 🇺🇸
Moses H Cone Memorial Hosp, Greensboro, North Carolina, United States
🇺🇸State of MD Div of Corrections / Johns Hopkins Univ Hosp, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
The Treatment of Tuberculosis in HIV-Infected Patients
- Conditions
- HIV InfectionsTuberculosis
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 650
- Registration Number
- NCT00001033
- Locations
- 🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.